When stem cell industry innovators from across the globe congregated in Miami at the end of January 2020 to discuss the current state and future expectations of the regenerative medicine industry, Biorasi had more than one reason to be excited about the event. Read the full article for highlights >>
To unlock more targeted, effective treatments, genetics researchers are exploring mutations responsible for some of the most common motor neuron diseases. These discoveries may lead to gene therapy treatment routes that do a better job of slowing disease progression than current medications. Much like gene therapy in oncology has brought improvement in cancer regression in recent years, we believe gene therapy—particularly therapy that targets and modulates RNA—is the future of neurology.
Run a more efficient pediatric clinical trial: Although pediatric trials overall cost roughly the same as adult clinical trials according to one analysis, they generally produce a more modest return on investment.
Movement disorders such as Parkinson’s disease, ataxias, tremor, dystonia, tics, Tourette’s, and dozens of rare diseases, […]
Less than a year ago, FDA approved the first cannabinoid-derived drug, Epidiolex. It’s a […]
“Microbiome” has become a consumer product buzzword, found in advertisements for soap and dozens […]
The numbers vary but multiple surveys confirm what we all know: patient recruitment is […]
Neurological disorders and diseases affect all ages and ethnicities, and most result in long-term disability […]
In a statement last August, departing FDA Commissioner Scott Gottlieb outlined several steps the agency had […]
Advances in stroke management, the first cannabinoid-derived drug approved, new therapeutics for progressive multiple […]
Site selection is one of the most crucial parts of planning a study. Ensuring that sites are performing up to par while a trial is underway is equally important but often neglected. Biorasi was asked to assist in a phase II trial of stem cell therapy for traumatic brain injury (TBI).
